Catalyst

Slingshot members are tracking this event:

Sarepta (SRPT) Expects to Complete Dose-Titration and Open-label Extension Phase 1 Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients in April 2018

Source Link:
http://seekingalpha.com/article/3651996-sarepta-therapeutics-srpt-ceo-ed-kaye-q3-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SRPT
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details
Estimated Completion Date: April 2018

Recruitment Status: Active, not recruiting
https://www.clinical...
Additional Relevant Details In Fall 2015, Sarepta added a third exon-skipping candidate SRP-4045 to the clinical trial stage for the treatment of duchenne muscular dystrophy, specifically the skipping of exon-45.  The Phase 1 trial was initiated and achieved first-patient dosing in 2015.  The study was originally projected to be completed Q2 of 2016.
https://www.clinical...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 26, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02530905
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Exon Skipping, Skipping Exon 45, Duchenne Muscular Dystrophy, Genetic Mutation, Srp-4045
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.